Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112


14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.

Kim IK, Park SM, Cho HJ, Baek KE, Nam IK, Park SH, Ryu KJ, Ryu J, Choi J, Hong SC, Kim JW, Lee CW, Kang SS, Yoo J.

Oncotarget. 2013 Nov;4(11):2045-56.


VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.

Cho HJ, Kim IK, Park SM, Baek KE, Nam IK, Park SH, Ryu KJ, Choi J, Ryu J, Hong SC, Jeong SH, Lee YJ, Ko GH, Kim J, Won Lee C, Soo Kang S, Yoo J.

Int J Cancer. 2014 Oct 1;135(7):1553-63. doi: 10.1002/ijc.28801. Epub 2014 Mar 4.


RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.

Cho HJ, Baek KE, Park SM, Kim IK, Nam IK, Choi YL, Park SH, Im MJ, Choi J, Ryu J, Kim JW, Lee CW, Kang SS, Yoo J.

Cancer Lett. 2011 Dec 1;311(1):48-56. doi: 10.1016/j.canlet.2011.06.024. Epub 2011 Jun 24.


FBXL5 attenuates RhoGDI2-induced cisplatin resistance in gastric cancer cells.

Wu WD, Wang M, Ding HH, Qiu ZJ.

Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2551-7.


PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.

Cho HJ, Baek KE, Nam IK, Park SM, Kim IK, Park SH, Im MJ, Ryu KJ, Yoo JM, Hong SC, Kim JW, Lee CW, Yoo J.

Biochem Biophys Res Commun. 2011 Oct 28;414(3):575-80. doi: 10.1016/j.bbrc.2011.09.121. Epub 2011 Oct 1.


RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells.

Cho HJ, Park SM, Kim IK, Nam IK, Baek KE, Im MJ, Yoo JM, Park SH, Ryu KJ, Han HT, Kim HJ, Hong SC, Kim KD, Pak Y, Kim JW, Lee CW, Yoo J.

Oncotarget. 2014 Mar 30;5(6):1554-64.


Proteomics-based strategy to delineate the molecular mechanisms of RhoGDI2-induced metastasis and drug resistance in gastric cancer.

Cho HJ, Baek KE, Kim IK, Park SM, Choi YL, Nam IK, Park SH, Im MJ, Yoo JM, Ryu KJ, Oh YT, Hong SC, Kwon OH, Kim JW, Lee CW, Yoo J.

J Proteome Res. 2012 Apr 6;11(4):2355-64. doi: 10.1021/pr2011186. Epub 2012 Mar 12.


RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway.

Niu H, Wu B, Peng Y, Jiang H, Zhang Y, Wang J, Zhang Y, He P.

Tumour Biol. 2015 Jan;36(1):409-19. doi: 10.1007/s13277-014-2671-9. Epub 2014 Sep 30. Erratum in: Tumour Biol. 2015 Jan;36(1):459.


RhoGDI2 is associated with HGF-mediated tumor invasion through VEGF in stomach cancer.

Koh SA, Kim MK, Lee KH, Kim SW, Kim JR.

Clin Exp Metastasis. 2014 Oct;31(7):805-15. doi: 10.1007/s10585-014-9671-4. Epub 2014 Sep 25.


Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.

Liu HZ, Yu C, Yang Z, He JL, Chen WJ, Yin J, Li WM, Liu HT, Wang YX.

Mol Med Rep. 2011 Sep-Oct;4(5):985-92. doi: 10.3892/mmr.2011.513. Epub 2011 Jun 17.


RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.

Cho HJ, Baek KE, Park SM, Kim IK, Choi YL, Cho HJ, Nam IK, Hwang EM, Park JY, Han JY, Kang SS, Kim DC, Lee WS, Lee MN, Oh GT, Kim JW, Lee CW, Yoo J.

Clin Cancer Res. 2009 Apr 15;15(8):2612-9. doi: 10.1158/1078-0432.CCR-08-2192. Epub 2009 Apr 7.


14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.

Lai KK, Chan KT, Choi MY, Wang HK, Fung EY, Lam HY, Tan W, Tung LN, Tong DK, Sun RW, Lee NP, Law S.

Tumour Biol. 2016 Feb;37(2):2127-36. doi: 10.1007/s13277-015-4018-6. Epub 2015 Sep 8.


DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance.

Danilov AV, Neupane D, Nagaraja AS, Feofanova EV, Humphries LA, DiRenzo J, Korc M.

PLoS One. 2011;6(10):e26815. doi: 10.1371/journal.pone.0026815. Epub 2011 Oct 28.


HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.

Ribeiro JR, Schorl C, Yano N, Romano N, Kim KK, Singh RK, Moore RG.

J Ovarian Res. 2016 May 17;9(1):28. doi: 10.1186/s13048-016-0240-0.


Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma.

Yi B, Hu Y, Qin G, Gu W, Zhu X, He S, Zhou J, Li D.

Int J Mol Med. 2014 Jul;34(1):205-12. doi: 10.3892/ijmm.2014.1765. Epub 2014 Apr 30.


Protein inhibitor of activated STAT-1 is downregulated in gastric cancer tissue and involved in cell metastasis.

Chen P, Zhao D, Sun Y, Huang L, Zhang S, Yuan Y.

Oncol Rep. 2012 Dec;28(6):2149-55. doi: 10.3892/or.2012.2030. Epub 2012 Sep 12.


Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.

Wu Y, McRoberts K, Berr SS, Frierson HF Jr, Conaway M, Theodorescu D.

Oncogene. 2007 Feb 1;26(5):765-73. Epub 2006 Jul 31.


Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells.

Cetintas VB, Tetik A, Cok G, Kucukaslan AS, Kosova B, Gunduz C, Veral A, Eroglu Z.

Cell Biol Int. 2013 Jan;37(1):78-86. doi: 10.1002/cbin.10006. Epub 2012 Nov 14.


Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.

Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX.

J Biol Chem. 2003 May 23;278(21):19245-56. Epub 2003 Mar 12.


Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.

Zhang L, Yang X, Li X, Li C, Zhao L, Zhou Y, Hou H.

Int J Mol Med. 2015 Oct;36(4):957-66. doi: 10.3892/ijmm.2015.2324. Epub 2015 Aug 24.

Supplemental Content

Support Center